|Mr. Richard C. Goldstein||Co-Founder, CFO & Director||104.76k||N/A||1962|
|Mr. Barry M. Polisuk||Sec. & Independent Director||50.34k||N/A||1960|
|Mr. Lawrence Latowsky||Chief Exec. Officer||N/A||N/A||1961|
|Mr. Joshi Laxminarayan||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Eric Malinski||Director of Marketing||N/A||N/A||N/A|
Canntab Therapeutics Limited, a biopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids, tetrahydrocannabinol, and terpenes in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
Canntab Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.